ArticleEMBO molecular medicine2022
Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer.
Article in EMBO molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Protocol for single-cell epigenetic profiling in human organoids and tumoroids with Epi-CyTOF.STAR protocols · 2026Article
- Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Towards functional precision medicine? Evidence standards of organoids as patient-specific models.History and philosophy of the life sciences · 2026Article
- Epithelial WNT secretion drives niche escape of developing gastric cancer.Molecular cancer · 2025Article
- Analysis of perioperative chemotherapy-mediated genomic changes in gastric cancer.BMC gastroenterology · 2025Article
- Non-coding RNAs-mediated regulation of the MAPK pathway in gastric cancer: translational perspectives.Discover oncology · 2025Review
- WSGC@FA@PEG/PEI-SPIONs Mitigate Chemoresistance in Gastric Adenocarcinoma by Modulating the Notch Signaling Pathway and Mitophagy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Delactylase effects of SIRT1 on a positive feedback loop involving the H19-glycolysis-histone lactylation in gastric cancer.Oncogene · 2025Article
- Single-cell transcriptomics reveals the multidimensional dynamic heterogeneity from primary to metastatic gastric cancer.iScience · 2025Article
- Osteoblast-Derived ECM1 Promotes Anti-Androgen Resistance in Bone Metastatic Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The role of MAPK pathway in gastric cancer: unveiling molecular crosstalk and therapeutic prospects.Journal of translational medicine · 2024Review
- Gastric Organoid, a Promising Modeling for Gastric Stem Cell Homeostasis and Therapeutic Application.International journal of stem cells · 2024Review
- Unraveling the influence of LncRNA in gastric cancer pathogenesis: a comprehensive review focus on signaling pathways interplay.Medical oncology (Northwood, London, England) · 2024Review
- Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer.International journal of molecular sciences · 2024Review
- Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review.Frontiers in oncology · 2024Review
- The dysregulation of PARP9 expression is linked to apoptosis and DNA damage in gastric cancer cells.PloS one · 2024Article
- Novel mutations in a second primary gastric cancer in a patient treated for primary colon cancer.World journal of surgical oncology · 2023Review
- The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.Journal of experimental & clinical cancer research : CR · 2023Article
- HDAC-an important target for improving tumor radiotherapy resistance.Frontiers in oncology · 2023Review
- Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway activation in gastric cancer.EMBO molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer ranks the fifth most common and third leading cause of cancer-related deaths worldwide. Alterations in the RTK/MAPK, WNT, cell adhesion, TP53, TGFβ, NOTCH, and NFκB signaling pathways could be identified as main oncogenic drivers. A combination of altered pathways can be associated with molecular subtypes of gastric cancer. In order to generate model systems to study the impact of different pathway alterations in a defined genetic background, we generated three murine organoid models: a RAS-activated (Kras
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.